These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
349 related articles for article (PubMed ID: 3013785)
1. Increased incidence of IgA antibodies to the Epstein-Barr virus-associated viral capsid antigen and early antigens in patients with chronic lymphocytic leukemia. Dölken G; Bross KJ; Hecht T; Brugger W; Löhr GW; Hirsch FW Int J Cancer; 1986 Jul; 38(1):55-9. PubMed ID: 3013785 [TBL] [Abstract][Full Text] [Related]
2. [Demonstration of IgG- and IgA-antibodies against Epstein-Barr virus-associated antigens with a microtiter enzyme immunoassay system. The determination of serum antibodies against the viral capsid antigen and the early antigen complex in the sera of tumor and infectious mononucleosis patients]. Dölken G; Bitzer M; Bross KJ; Brugger W; Boldt C; Hirsch FW; Weitzmann U; Löhr GW Dtsch Med Wochenschr; 1984 Nov; 109(48):1837-43. PubMed ID: 6094138 [TBL] [Abstract][Full Text] [Related]
3. Antibodies to Epstein-Barr virus-specific antigens in patients with hairy-cell leukemia. Sakamoto K; Aiba M; Katayama I; Sullivan JL; Humphreys RE; Purtilo DT Int J Cancer; 1981; 27(4):453-8. PubMed ID: 6268553 [TBL] [Abstract][Full Text] [Related]
4. Significance of plasma IgA and IgG antibodies to Epstein-Barr virus early and viral capsid antigens in Thai nasopharyngeal carcinoma. Tiwawech D; Srivatanakul P; Karaluk A; Ishida T Asian Pac J Cancer Prev; 2003; 4(2):113-8. PubMed ID: 12875623 [TBL] [Abstract][Full Text] [Related]
5. Significance of specific Epstein-Barr virus IgA and elevated IgG antibodies to viral capsid antigens in nasopharyngeal carcinoma patients. Hadar T; Rahima M; Kahan E; Sidi J; Rakowsky E; Sarov B; Sarov I J Med Virol; 1986 Dec; 20(4):329-39. PubMed ID: 3025351 [TBL] [Abstract][Full Text] [Related]
6. Detection of IgA antibodies to Epstein-Barr virus-associated antigens by ELISA. Dölken G; Weitzmann U; Boldt C; Bitzer M; Brugger W; Löhr GW J Immunol Methods; 1984 Mar; 68(1-2):331-9. PubMed ID: 6368695 [TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Henle G; Henle W Int J Cancer; 1976 Jan; 17(1):1-7. PubMed ID: 175020 [TBL] [Abstract][Full Text] [Related]
8. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma. Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282 [TBL] [Abstract][Full Text] [Related]
9. Prevalence of IgA specific antibodies to Epstein-Barr virus capsid and early antigens in nasopharyngeal carcinoma. Puthavathana P; Kositanont U; Chongkolwatana C; Metheetrairut C; Chantarakul N; Nuntarakchaikul S; Wasi C Asian Pac J Allergy Immunol; 1993 Jun; 11(1):39-43. PubMed ID: 8216557 [TBL] [Abstract][Full Text] [Related]
10. Relationship between clinical stage, histopathology and antibody titers against the second Epstein-Barr virus nuclear antigen (EBNA-2) in non-Hodgkin's lymphoma patients. Masucci G; Mellstedt H; Henle G; Henle W; Rymo L; Masucci MG; Ernberg I; Klein G Int J Cancer; 1989 Jun; 43(6):1017-21. PubMed ID: 2543639 [TBL] [Abstract][Full Text] [Related]
11. IgG and IgA antibodies to Epstein-Barr virus in nasopharyngeal carcinoma patients. Gong SH; Lynn TC; Yang CS Zhonghua Min Guo Wei Sheng Wu Xue Za Zhi; 1978 Mar; 11(1):8-15. PubMed ID: 211015 [TBL] [Abstract][Full Text] [Related]
12. Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening. Fachiroh J; Paramita DK; Hariwiyanto B; Harijadi A; Dahlia HL; Indrasari SR; Kusumo H; Zeng YS; Schouten T; Mubarika S; Middeldorp JM J Clin Microbiol; 2006 Apr; 44(4):1459-67. PubMed ID: 16597877 [TBL] [Abstract][Full Text] [Related]
13. Expression of EBV antibody EA-IgA, Rta-IgG and VCA-IgA and SA in serum and the implication of combined assay in nasopharyngeal carcinoma diagnosis. Xia C; Zhu K; Zheng G Int J Clin Exp Pathol; 2015; 8(12):16104-10. PubMed ID: 26884888 [TBL] [Abstract][Full Text] [Related]
14. Establishment of VCA and EBNA1 IgA-based combination by enzyme-linked immunosorbent assay as preferred screening method for nasopharyngeal carcinoma: a two-stage design with a preliminary performance study and a mass screening in southern China. Liu Y; Huang Q; Liu W; Liu Q; Jia W; Chang E; Chen F; Liu Z; Guo X; Mo H; Chen J; Rao D; Ye W; Cao S; Hong M Int J Cancer; 2012 Jul; 131(2):406-16. PubMed ID: 21866545 [TBL] [Abstract][Full Text] [Related]
15. Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, tonsillar carcinoma and control groups. Oberender H; Nowak R; Donner A; Kunkel M; Gärtner L; Scholtz HJ Acta Virol; 1983 May; 27(3):277-81. PubMed ID: 6138990 [TBL] [Abstract][Full Text] [Related]
16. The reliability of IgA antibody to Epstein-Barr virus (EBV) capsid antigen as a test for the diagnosis of nasopharyngeal carcinoma (NPC). Levine PH; Pearson GR; Armstrong M; Bengali Z; Berenberg J; Easton J; Goepfert H; Henle G; Henle W; Heffner D; Huang A; Hyams VJ; Lanier A; Neel HB; Pilch B; Pointek N; Taylor W; Terebelo H; Weiland L Cancer Detect Prev; 1981; 4(1-4):307-12. PubMed ID: 6299561 [TBL] [Abstract][Full Text] [Related]
17. [Evaluation of IgG and IgA type antibodies to capsid and early antigens of the Epstein-Barr virus in the diagnosis of nasopharyngeal carcinoma]. Mendoza J; Rojas A; de la Rosa M; Amador JM; Expósito J; Esquivias J Med Clin (Barc); 1991 Nov; 97(16):609-11. PubMed ID: 1662737 [TBL] [Abstract][Full Text] [Related]
18. Prognostic value of anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma (NPC). Liu MT; Yeh CY Radiat Med; 1998; 16(2):113-7. PubMed ID: 9650898 [TBL] [Abstract][Full Text] [Related]